

## 해외 바이오의약품 임상 현황 (2020.10.19~2020.10.25)

한국바이오의약품협회, 2020.10.27  
출처: ClinicalTrials.gov

### ○ 미국 17건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04585815	Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non Small Cell Lung Cancer	Carcinoma, Non-Small-Cell Lung	Drug: Sasanlimab Prefilled syringe Drug: Encorafenib Drug: Binimetinib	Pfizer	Phase 1  Phase 2
NCT04562610	Enhanced Recovery After Surgery in Orthopaedic Spine Surgery	Lumbar Surgery	Drug: Intravenous Infusion group Drug: All oral administration group	University of California, Davis	Phase 2  Phase 3
NCT04464759	A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma	Melanoma	Drug: Nivolumab Drug: Hydroxychloroquine Drug: Ipilimumab	Ravi Amaravadi, MD Bristol-Myers Squibb Abramson Cancer Center of the University of Pennsylvania	Phase 1  Phase 2
NCT04591717	Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers	COVID-19	Biological: hAd5-S-Fusion+N-ETSD vaccine	ImmunityBio, Inc.	Phase 1
NCT04558346	Ghrelin (OXE--103) for Acute Concussion Management	Concussion, Brain Traumatic Brain Injury	Drug: Ghrelin (OXE-103) Drug: Placebo	Michael Rippee, MD University of Kansas Health System University of Kansas Medical Center	Phase 2
NCT04262167	Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis	Biological: Lung Spheroid Stem Cells 100 million Biological: Lung Spheroid Stem Cells 200 million	University of North Carolina, Chapel Hill National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
NCT04225676	Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)	ALL	Biological: Tisagenlecleucel	Novartis Pharmaceuticals Novartis	Phase 2
NCT04479241	PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma	Glioblastoma Recurrent Glioblastoma Supratentorial Glioblastoma Brain Tumor	Biological: PVSRIPO Biological: pembrolizumab	Istari Oncology, Inc.	Phase 1
NCT04413123	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC	Papillary Renal Cell Carcinoma Unclassified Renal Cell Carcinoma Translocation Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Collecting Duct Renal Cell Carcinoma Medullary Renal Cell Carcinoma Renal Cell Carcinoma Unresectable Advanced Renal Cell Carcinoma Metastatic Ncc Renal Cell Carcinoma	Drug: Cabozantinib Drug: Nivolumab Drug: Ipilimumab	Bradley A. McGregor Bristol-Myers Squibb Exelixis Dana-Farber Cancer Institute	Phase 2
NCT04370236	INB03 for the Treatment of Pulmonary Complications From COVID-19	COVID-19	Drug: INB03 Drug: Placebo	Inmune Bio, Inc.	Phase 2  Phase 3
NCT04404595	Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer	Gastric Cancer Pancreatic Cancer	Biological: CT041	Carsgen Therapeutics, Ltd.	Phase 1
NCT04521621	A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)	Neoplasm Metastasis	Biological: V937 Drug: Pembrolizumab	Merck Sharp & Dohme Corp.	Phase 1  Phase 2
NCT04583969	ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19	COVID-19	Biological: Lenzilumab Other: Placebo Drug: Remdesivir	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
NCT04599933	An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-1)	Presbyopia	Drug: CSF-1 Drug: Vehicle	Orasis Pharmaceuticals Ltd.	Phase 3
NCT04539275	COVID-19 (VA CURES-1)	COVID-19	Drug: Convalescent Plasma Other: Masked Saline Placebo	VA Office of Research and Development	Phase 3
NCT04537923	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	Type 2 Diabetes	Drug: Tirzepatide Drug: Insulin Lispro (U100) Drug: Insulin Glargine (U100)	Eli Lilly and Company	Phase 3
NCT04560569	Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection	HIV/AIDS	Drug: Albuvirtide Drug: 3BNC117 Antibody	Frontier Biotechnologies Inc.	Phase 2

## 해외 바이오의약품 임상 현황 (2020.10.19~2020.10.25)

한국바이오의약품협회, 2020.10.27  
출처: ClinicalTrials.gov

### ○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04537923	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	Type 2 Diabetes	Drug: Tirzepatide Drug: Insulin Lispro (U100) Drug: Insulin Glargine (U100)	Eli Lilly and Company	Phase 3

### ○ 중국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04538911	Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients	Tuberculosis	Drug: BCG-PPD	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) Beijing Kangterike Statistical Technology Co., Ltd.	Phase 1
NCT04034615	The Long-term Effect of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars	Cicatrix	Biological: Mesenchyme Stem Cells low-dose group Biological: Mesenchyme Stem Cells high-dose group Biological: Placebo	Maternal and Child Health Hospital of Foshan	Phase 2

### ○ 일본 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04498832	Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older	Influenza (Healthy Volunteers)	Biological: High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD) Biological: Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)	Sanofi Pasteur, a Sanofi Company Sanofi	Phase 3
NCT04588480	Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults	SARS-CoV-2 Infection COVID-19	Biological: BNT162b2 Other: Placebo	BioNTech SE Pfizer	Phase 1